Navigation Links
Boston Scientific Completes Enrollment in Landmark Heart Failure Trial
Date:4/24/2008

NATICK, Mass., April 24 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced completion of enrollment in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). The trial includes 1,820 patients and examines the potential benefits of Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) in a new population of heart failure patients. It is the latest in a series of landmark randomized clinical trials sponsored by Boston Scientific's Cardiac Rhythm Management group, following in the tradition of MADIT, MADIT II and COMPANION.

MADIT-CRT is designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function. The trial may demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure (as defined by the New York Heart Association as Class I and II) to late-stage heart failure (Class III and IV).

"This study builds on the observations made in the COMPANION trial, which evaluated the benefits of CRT-D therapy in patients with late-stage, symptomatic heart failure," said Arthur Moss, M.D., Professor of Medicine at the University of Rochester, NY, and Principal Investigator of MADIT-CRT. "If positive, this trial may address the still unanswered question about the potential of resynchronization defibrillator therapy to inhibit the clinical progression of heart failure through earlier intervention."

"Boston Scientific is proud to sponsor MADIT-CRT, an important continuation of more than a decade of MADIT family trials," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "This robust study design was created by leading cardiologists and is supported by medical science with appropriate endpoints to determine whether CRT-Ds can slow the progression of heart failure in Class I and II patients."

Approximately 70 percent of all heart failure patients fall into Class I or II. Nearly 22 million people worldwide, including approximately 5.5 million Americans, currently suffer from some form of heart failure. Nearly one million new cases of heart failure are diagnosed annually worldwide, making it the most rapidly growing cardiovascular disorder.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Scientific Named Healthcare Supplier of the Year by Global Healthcare Exchange (GHX)
2. Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices
3. DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
4. Boston Trial to Test New HIV/AIDS Vaccine
5. Boston College biologists build a better mouse model for cancer research
6. Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs
7. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
8. Boston Kids Enjoy Free Davis Vision Screenings
9. Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Media Invited to Attend International Society for Heart & Lung Transplantation Meeting in Boston, April 9-12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: